Study details
Enrolling now
Iodine I 131 Metaiodobenzylguanidine for Certain Cancers
Memorial Sloan Kettering Cancer Center
NCT IDNCT00107289ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
200
Study length
about 20 years
Ages
1+
Locations
1 site in NY
What this study is about
Researchers are testing if iodine I 131 metaiodobenzylguanidine (MIBG) is an effective and safe treatment for patients with recurrent, progressive, or refractory neuroblastoma, malignant pheochromocytoma, or paraganglioma. The trial will involve adults and children, and the estimated trial length is 7305 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take iobenguane I 131
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
iobenguane (131I)
Body systems
Oncology